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Abstract
Background: Intermittent preventive treatment for malaria in Infants (IPTi) has been shown to give effective and safe
protection against malaria. It has been suggested that IPTi might have long-lasting beneficial effects but, in most settings,
the protection provided by IPTi appears to be short-lived. Knowledge of the duration of protection given by IPTi would help
interpret the results of existing trials and suggest optimal delivery schedules for IPTi. This study investigated how the
protective efficacy of IPTi against malaria and anaemia changes over time.
Methods and Findings: A secondary analysis of data from a cluster-randomised, placebo-controlled trial of IPTi using
sulfadoxine-pyrimethamine (SP) in Ghana was conducted. In this trial IPTi was given to 2485 infants at 3, 4, 9 and 12 months
of age; children remained in follow-up until two years of age. Poisson regression with a random effect to adjust for the
cluster-randomised design was used to determine protective efficacy of IPTi against clinical malaria and anaemia in defined
time strata following administration of IPTi. Analysis of first-or-only clinical malaria episode following the individual IPTi
doses showed that some protection against malaria lasted between 4 to 6 weeks. A similar pattern was seen when the
incidence of all malaria episodes up to 2 years of age was analysed in relation to the most recent IPT, by pooling the
incidence of malaria after the individual IPTi doses. Protective efficacy within four weeks of IPTi was 75.2% (95% CI: 66–82)
against malaria, 78.9% (95% CI: 69–86) against high parasite density malaria, and 93.8% (95% CI: 73–99) against anaemia.
Protection against these outcomes was short-lived, with evidence of any effect lasting for only 6, 6 and 4 weeks respectively.
Protection in children who were parasitaemic when receiving IPTi appeared to be of shorter duration than in uninfected
children. There was no evidence of any benefit of IPTi after the immediate period following the IPTi doses.
Conclusions: Intermittent preventive treatment provides considerable protection against malaria and anaemia for short
periods, even in an area of intense seasonal transmission. Due to the relatively short duration of protection provided by
each dose of IPTi, this treatment will be of most benefit when delivered at the time of peak malaria incidence.
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Introduction
Intermittent preventive treatment (IPT) is a promising strategy
for preventing malaria morbidity in infants and children,
particularly in sub-Saharan Africa where the disease burden is
highest. Sulfadoxine-pyrimethamine (SP) given to Tanzanian
infants alongside routine vaccinations gave high protective efficacy
against malaria and anaemia; this protection appeared to be
sustained long after the chemoprophylactic period of SP,
suggesting that development of protective immunity might have
been facilitated by the treatment [1–3]. Subsequent studies in
infants and children have shown IPT to be an effective preventive
measure against malaria, but none of these have shown a sustained
benefit beyond the period that might reasonably be attributed to
drugs [4–12]. The most likely explanation is that IPT reduces the
incidence of malaria primarily through clearing existing parasit-
aemia (or reducing it to a level below the fever threshold) and
preventing new infections sensitive to the drug used for IPT [13].
Although there is now a large body of evidence that three
courses of IPT given alongside Expanded Programme on
Immunisation (EPI) vaccines can reduce the incidence of malaria
in infants, the optimum timing and frequency of IPT doses is still
debated [14]. The EPI-linked IPT schedule was based on the
feasibility of delivering IPT rather than on maximising its potential
benefits. Data on the duration of protection following each dose of
IPT would help to define the optimum interval between IPT
doses, enabling development of the optimal delivery strategy for a
given location. Knowledge of how long IPT gives protection for
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might also explain the differences in efficacy observed when
different delivery strategies for IPT have been used. For example,
four doses of IPT delivered to infants through the EPI in Ghana
achieved a protective efficacy (PE) of 24.8% (95% confidence
interval (CI) 14.3–34.0) over a twelve-month period [4], whereas
monthly IPT given to children under 5 in Senegal over a three-
month period achieved protective efficacy of 86%; (95% CI: 80–
90) [5].
Methods
This study used data from a cluster randomized trial of IPTi in
Navrongo, Ghana described in detail elsewhere [4]. In brief, four
doses of SP or placebo were given to infants at 3, 4 and 9 months of
age at time of vaccinations delivered through the EPI, and at the 12
month growth-monitoring visit. Individual doses of IPTi are referred
to as IPT-1, IPT-2, etc. Primary endpoints in the trial were clinical
malaria (history of fever or temperature $37.5uC plus malaria
parasites detected on a blood smear) detected in children attending
health centres or the hospital and anaemia (packed cell volume
,24%) in children admitted to the study hospital for any illness; the
same endpoints have been used for this analysis. High parasite
density malaria episodes as defined in the trial (malaria with parasite
density $5000 parasites/ml) were also examined.
Covariates pre-specified for adjustment in analysis of the main
trial were sex, urban residence and mosquito net usage. Reported
bednet use among study children was low (13%) and insecticide
treated net use very low (2%); there were no data for 26% of
children. For this reason bednet use was not included in the
models. The primary analysis was performed unadjusted for
covariates; the effect of adjusting for age at time of dose, sex and
place of residence (rural or urban) was then explored.
Protective efficacy of individual IPT doses
Person time at risk of malaria was calculated from the date of a
given dose of IPTi until a subsequent dose was administered,
malaria was diagnosed, or the individual exited the study (dropped
out, migrated or died), whichever occurred first. Kaplan-Meier
failure plots were used to examine incidence of malaria after each
IPTi dose until the following IPTi dose or until the end of follow
up. A poisson regression model was fitted with a gamma
distributed random effect to account for potential correlation
within clusters of children. Lexis expansion [15] was used to
examine malaria incidence in defined strata following each dose of
IPTi, allowing week-specific estimates of protective efficacy (1-
Incidence rate ratio, IRR (SP versus placebo)%) to be calculated.
Evidence for interaction between time since receiving IPTi and
protective efficacy was assessed using the likelihood ratio test
(LRT), initially without adjusting for covariates, and after
including the covariates age, sex and place of residence (rural or
urban) in the model.
Protective efficacy against all malaria and anaemia
episodes up to two years of age
Person time at risk of malaria and anaemia was calculated from
first dose of IPT until the child exited the study or reached two
years of age. Lexis expansion was performed and a variable was
created that showed the number of weeks since the most recent
treatment throughout follow-up. This allowed incidence of any
malaria or anaemia episode that occurred between the first
treatment and two years of age to be related to time since most
recent IPTi dose; pooling the analysis across doses enabled a more
robust analysis of protective efficacy over time. For malaria and
high parasite density malaria, follow-up was stratified by week
since IPT; there were fewer episodes of anaemia so two-week
strata were used. Incidence rate in a given time stratum was
compared between trial arms using a poisson regression model
with a cluster-level random effect.
Participants who had received chloroquine or quinine, the drugs
of choice during the study period, for the treatment of clinical
episodes of malaria were not considered to be free of the risk of
malaria during the post treatment period. This approach gives a
more pragmatic estimate of the effect of IPTi, by making a direct
comparison between IPTi and routine case-management of
malaria. Consequently, our estimate of the protective efficacy of
IPTi may be slightly more conservative than that reported by
other studies that deducted 3 to 4 weeks post treatment for each
episode of malaria to account for the prophylactic effect of the
antimalarial treatment.
To investigate if protection in Navrongo was compatible with
that reported from studies that have used monthly IPT, an analysis
that only included episodes that occurred within four weeks of an
IPTi dose was performed.
Effect of parasitaemia on protective efficacy of IPTi
In addition to providing prophylaxis, IPT should in most cases
clear parasitaemia present at the time of treatment. This could be
beneficial since many children in this age group will not have
developed sufficient immunity to prevent an existing infection
increasing in density and causing disease [16]. However, in
children carrying low density infections that do not cause illness,
clearance of parasitaemia may not be advantageous as it could
result in the loss of cross-protective immunity against similar
parasite genotypes (premunition) and consequently increase the
risk of subsequent malaria [17,18]. To investigate this, protective
efficacy of IPT in children with and without microscopically
detected parasitaemia at time of IPT dose was compared.
The approach taken was the same as for the pooled analysis of
all malaria episodes: a poisson regression model was fitted to the
data and follow-up time stratified by week since most recent
treatment. Blood smears were not taken at the dose given at four
months of age (scheduled as IPT-2) but were available for 106
individuals who received IPT-2 at a later date due to vomiting or
absence at the scheduled time. Follow-up time after doses at which
parasitaemia was not determined was excluded from this analysis.
All analyses were performed in Stata version 9 (StataCorp,
College Station, Texas).
Ethical Approval
Ethical approval for this study was granted by the Ethics Review
Board of the London School of Hygiene and Tropical Medicine,
number 05/176.
Results
Protective efficacy of individual IPT doses
Kaplan-Meier failure plots for clinical malaria following individ-
ual IPTi doses are shown in figure 1. Length of follow-up time was
unrestricted in this analysis since the interval between doses could be
longer than scheduled if participants did not receive a subsequent
dose or received it late, but only the first 20 weeks following
treatment are presented. In the survival analysis of the protective
effect of IPT-1, most children received IPT-2 after 28 days.
Consequently, single episodes of malaria later in the survival curve
have a large effect because the number remaining at risk is small.
Poisson regression with a random effect to adjust for the
clustered design was used to estimate protective efficacy against
clinical malaria with increasing time since IPTi doses. Adjusting
Duration of IPT Protection
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for age, sex and place of residence of children made negligible
changes to the estimates of protective efficacy; data are presented
from the unadjusted models. There was strong evidence of an
interaction between IPT efficacy and time since IPT dose (LRT
p,0.01 in all analyses) suggesting that protective efficacy depends
on how long ago the IPT dose was received. Protection is high
initially but then appears to be lost rapidly. Consistent with other
IPTi studies, protective efficacy is presented up to twelve weeks (3
months) post dose. No evidence of either protective or detrimental
effects was observed after this period for any of the doses of IPTi.
For all IPT doses there is evidence of significant protection for at
least four weeks, protection appears to last for at least five weeks
after IPT-3 and there is weak evidence of some protection up to 6
weeks for IPT-2 (table 1 & figure 2). This analysis was not possible
for IPT-1 since this was followed in most cases by IPT-2 28 days
later and incidence of malaria was low even among children who
received placebo in this age group.
Protective efficacy against all malaria and anaemia
episodes up to two years of age
There was strong evidence of a high protective effect against all
episodes of clinical malaria and high parasite density malaria in
the first four to five weeks following IPT. Some protection was
seen up to six weeks but from seven weeks onwards there was no
evidence of any remaining benefit of having received IPTi.
Protection against anaemia was high up to four weeks after IPT.
No evidence of either a protective or detrimental effect was
observed after the immediate period following IPTi for any of
these outcomes. Our analysis included all of the follow-up period
to two years of age, but since no protective effect was observed
except for the immediate period following IPT, graphs are
truncated at 20 weeks post-dose (figures 3–5, table 2). Excluding
the first week after IPT, the point estimate of protective efficacy
declines with each successive week until efficacy approaches zero.
Adjusting for age, sex and place of residence of children again had
a negligible effect on the estimates of protective efficacy; data are
presented from the unadjusted models.
To compare the effect of our more pragmatic approach with
those of previous papers, we repeated the analysis removing 28
days of person-time at risk after a clinical malaria episode. The
results were remarkably similar to those presented, although there
was evidence of a small amount of protection against clinical
malaria lasting for an additional week after IPTi (i.e. into the
seventh week after treatment rather than the sixth week). After this
period there remained no evidence of any protection.
Comparison with seasonal IPT trials
Considering only incidence within the first four weeks
following a dose of IPT, protective efficacy was high: 75.2%
(95% CI: 66–82) against malaria, 78.9% (95% CI: 69–86) against
high parasite density malaria, and 93.8% (95% CI: 73–99) against
anaemia.
Figure 1. Kaplan-Meier failure plots for individual IPT doses. Kaplan-Meier plots showing cumulative proportion of children with a malaria
episode following IPT doses 1–4. Numbers below x-axis labels indicate number of children remaining in follow-up at that time point.
doi:10.1371/journal.pone.0002227.g001
Duration of IPT Protection
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Effect of parasitaemia on protective efficacy of IPTi
Individuals who are parasitaemic when given IPT experience a
higher incidence of malaria in the short term, but this risk wanes
with time. Within four weeks of treatment the incidence rate for
clinical malaria was 2.66 times greater in children who were
initially parasitaemic (95% CI: 2.12 to 3.34). There was no
evidence of interaction between parasitaemia and the overall
protective efficacy of IPT (LRT p=0.6521). However, there was
strong evidence of interaction between parasitaemia at time of
dose and the protective efficacy of IPT over time (LRT p,0.001).
Adjusting for age, sex and place of residence of children made
negligible changes to the estimates of protective efficacy; data are
presented from the unadjusted model. In children parasitaemic at
the time of IPT, protective efficacy is lower in the first week, but is
then high in the period up to 5 weeks following the IPTi dose.
There is a suggestion that protection may be lost faster in children
initially parasitaemic than in children without parasites (figure 6).
Discussion
Duration of protection given by IPTi
The protection provided by IPTi in Navrongo was of limited
duration. Protective efficacy against malaria and high parasite
density malaria was high during the first four to five weeks after
Figure 2. Protective efficacy of individual IPT doses against clinical malaria. Protective efficacy against first-or-only episode of clinical
malaria (history of fever or temperature $37.5uC plus malaria parasites detected on a blood smear) by week since treatment for IPTi doses 2, 3 & 4.
Error bars indicate 95% confidence intervals. The y-axis is truncated at2100 for IPT2 and IPT3, and at2150 for IPT4. No children given SP had malaria
during week 2 after IPT4.
doi:10.1371/journal.pone.0002227.g002
Duration of IPT Protection
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treatment, retaining some efficacy up to six weeks; there was no
evidence of a protective effect from week seven onwards.
Protection against anaemia lasted for four weeks following
treatment. Since periods when children were being treated for
malaria were not removed from time at risk in this analysis, our
estimate of protective efficacy may be slightly conservative and the
duration of protection slightly underestimated because more
episodes of malaria occurred in the placebo group. However,
removing 28 days person-time at risk after each malaria episode
increased the duration of protection following IPTi by just one
more week and there was no evidence of any protection after week
seven post IPTi. The period of highest protection was still within
the first four to five weeks. We do not therefore consider that our
conservative approach has resulted in any important underesti-
mation of the duration of protection given by IPTi.
There is weak evidence of an elevated incidence of malaria in
the SP group relative to those on placebo in weeks eight and nine
following IPT-4. Increased malaria incidence eight to ten weeks
after treatment with SP and artesunate was also observed in a
mass-drug administration trial in the Gambia [19]. However, this
effect was not seen in an analysis when multiple episodes of
malaria were considered rather than first-or-only episode (data not
shown) suggesting that this may be an artefact of frailty effects in
our survival analysis rather than rebound [20]. In other words,
children in the placebo group at high risk of malaria are likely to
have had malaria and exited the first-or-only episode analysis by
the time protection has worn off in the children given SP. This
means that the comparison at later time points is between almost
all children given SP (some of who are at high risk) and only the
placebo children at low risk of malaria. Even if this was a true
instance of minor rebound morbidity following IPT, it does not
appear to outweigh the episodes prevented by earlier protection.
The plasma half-lives of sulfadoxine and pyrimethamine are
between 5–11 days and 3–5 days respectively in adults, but there
are no data on pharmacokinetics in infants [13,21–23]. Direct
comparison of pharmacokinetic data with respect to the protection
observed is further hindered by the lack of an established
minimum inhibitory concentration in vivo. What can be expected
Table 1. Protective efficacy of individual IPT doses against
clinical malaria.
Protective Efficacy against clinical malaria (95%
Confidence Interval)
IPT-1 IPT-2
IPT dose IPT-2 IPT-3 IPT-4
Week since IPT
1 88 (0, 98) 92 (68, 98) 79 (43, 92)
2 92 (36, 99) 81 (51, 93) 100*
3 67 (22, 90) 85 (65, 94) 83 (54, 93)
4 83 (55, 93) 64 (30, 82) 64 (12, 85)
5 78 (42, 92) 74 (41, 88) 42 (216, 71)
6 55 (4, 79) 8 (267, 49) 14 (268, 56)
7 33 (231, 65) 18 (240, 52) 9 (272, 52)
8 37 (238, 71) 13 (257, 52) 295 (2302, 5)
9 31 (245, 67) 241 (2165, 25) 2136 (2394, 213)
10 23 (2109, 49) 17 (249, 53) 29 (2130, 48)
11 31 (227, 63) 18 (264, 59) 27 (2114, 47)
12 20 (241, 55) 244 (2181,27) 29 (254, 67)
Protective efficacy against first-or-only episode of clinical malaria (history of
fever or temperature $37.5uC plus malaria parasites detected on a blood
smear) by week since treatment for IPTi doses 2, 3 & 4.
*No children given SP had malaria during week 2 after IPT4.
doi:10.1371/journal.pone.0002227.t001
Figure 3. Protective efficacy of IPT against clinical malaria. Protective efficacy of IPTi by week since treatment against clinical malaria (history
of fever or temperature $37.5uC plus malaria parasites detected on a blood smear). Error bars indicate 95% confidence intervals. PE estimates are for
all IPT doses combined; all episodes that occurred before two years of age were included in the analysis. No long term protection was observed; for
brevity estimates are presented up to twenty weeks following treatment. Incidence in weeks 13–16 and 17–20 was aggregated; data points are
shown at the midpoint of each interval.
doi:10.1371/journal.pone.0002227.g003
Duration of IPT Protection
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is that the direct parasiticidal effect of treatment cannot last
indefinitely, and one would expect a gradual reduction in
protective efficacy which accelerates over time, as seen here
[23]. Watkins et al. have estimated that SP may be able to provide
prophylaxis against fully sensitive Plasmodium falciparum for
approximately 60 days [22]. Given that there was documented
SP resistance in the area at the time of the study and the
entomological inoculation rate (EIR) was high [24,25] one would
expect protection to be shorter than this, and indeed this is what
was observed. A pharmacokinetic study published since the
Figure 4. Protective efficacy of IPT against high parasite density malaria. Protective efficacy of IPTi by week since treatment against high
parasite density malaria (clinical malaria with parasite density $5000/ml). Error bars indicate 95% confidence intervals. PE estimates are for all IPT
doses combined; all episodes that occurred before two years of age were included in the analysis. No long term protection was observed; for brevity
estimates are presented up to twenty weeks following treatment. Incidence in weeks 13–16 and 17–20 was aggregated; data points are shown at the
midpoint of each interval.
doi:10.1371/journal.pone.0002227.g004
Figure 5. Protective efficacy of IPT against anaemia. Protective efficacy of IPTi by week since treatment against anaemia (packed cell volume
,24%). Error bars indicate 95% confidence intervals. PE estimates are for all IPT doses combined; all episodes that occurred before two years of age
were included in the analysis. No long term protection was observed; for brevity estimates are presented up to twenty weeks following treatment.
Weeks were aggregated as 1–2, 3–4, 5–6, 7–8, 9–10, 11–12, 13–16 & 17–20 weeks since treatment; data points are shown at the midpoint of each
interval. The y-axis is truncated at 2100, for full data see table 2.
doi:10.1371/journal.pone.0002227.g005
Duration of IPT Protection
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completion of this trial has shown that under-dosing of SP in
children may be widely under-recognised at present [26], which
could explain the apparent reduced duration of protection given
by later IPTi doses in older infants.
Comparison with seasonal IPT trials
Protective efficacy against clinical malaria within four weeks of
treatment was high: 75.2% (95% CI: 66–82). IPTi in this setting
therefore attains an efficacy similar to that achieved in Niakhar,
Senegal with monthly IPT (86%; 95% CI: 80–90)[5] when a
similar period after treatment is compared. The lower protective
efficacy during the entire study period (24.8%; 95% CI 14.3–34.0)
[4] is therefore a consequence of the prolonged periods between
IPT doses, rather than differing efficacy of each dose of IPTi. The
remaining difference in protective efficacy between these two sites
could be a consequence of the Niakhar trial including children up
to 5 years of age, artesunate being used in addition to SP, and the
lower transmission intensity in the Senegal site (estimated EIR in
Navrongo: 418 infective bites per year (2001–02) [25]; EIR in
Niakhar: 10 infective bites per year [5]).
Effect of parasitaemia on protective efficacy of IPTi
There was no evidence of an elevated incidence of malaria in
children who were parasitaemic when given IPT that would suggest
that clearance of parasites results in loss of cross protective immunity
against similar parasite genotypes and has a cost attached. In fact it
appears that infections that are asymptomatic at time of detection are
likely to lead to disease in the short term in this age group and should
be treated, a finding that agrees with existing literature on this
subject. A study in Uganda found that asymptomatic parasitaemia
was a clear risk factor for clinical malaria within thirty days of
detection [27], while a recent analysis of data from eight countries in
sub-Saharan Africa found that asymptomatic parasitaemia after
treatment carried a substantial risk of malaria within days of
discovery, particularly in young children [28].
Parasitaemic children experienced a markedly increased
incidence in the first week after IPT, even those who were given
SP. This effect was not age-related, so cannot be solely due to the
possible under-dosing in older children. Presumably this reflects
cases where the drug was given too late to prevent an incipient
episode since antimalarial drugs do not reduce the parasite burden
instantaneously, even if given intravenously [29]. Early treatment
failures for therapeutic use of SP in Navrongo at the time of the
study was 8.6% (95% CI 4.2, 15.3) [24].
For children free of parasites when they received IPT, the
protective efficacy profile reflects the ‘true’ prophylactic effect of
SP over time. Children who are parasitaemic are at the additional
risk of recrudescence of the original infection if the parasite is
resistant to SP, so protection may appear to last for less time than
in uninfected children. Existing knowledge suggests that use of
long acting antimalarials such as SP may result in very late
recrudescence if not all parasites are killed but multiplication is
suppressed until most of the drug is eliminated [23,30]. There is a
suggestion of this pattern in our results: protective efficacy for
parasitaemic children falls towards zero more rapidly than in
children free of parasitaemia (figure 6). We do not have data on
parasite genotypes with which to differentiate true recrudescence
from re-infections. An alternative explanation is that children
parasitaemic at time of treatment are more exposed to malaria
infection in general, so are more likely to be infected and develop
malaria in the follow-up period after IPT. In the short-term period
after IPT, however, the existing infection might be considered as
the more likely cause of malaria, given the resistance patterns in
Navrongo at the time and differing efficacy of SP as a therapeutic
and prophylactic agent (discussed below) [24].
The protective efficacy curves including children with and without
parasitaemia together (figures 3, 4 & 5) remain of primary interest
since they show the overall protection given that some children were
infected when given IPT and some were not. This will be the case in
almost all situations in which IPT is used. However, identification of
the possible relationship between parasitaemia and apparent
duration of IPT protection may help to interpret the results of
subsequent trials. The estimate of protective efficacy obtained from a
trial will be a function of the extent of protection and the duration for
which this protection appears to last. Consequently, protective
efficacy estimates could be affected by the proportion of children
infected at time of treatment as well as by levels of resistance to the
antimalarial used. Increase in either of these factors would predict
the duration of protection to be shorter and the estimate of protective
efficacy to be smaller. Post-treatment prophylaxis may indeed be a
more important component of IPT in infants than preventing
recrudescence [13,23]. However, for a given level of drug resistance,
if prevalence of infection at time of treatment rises, clearance of the
existing infection will increase in importance in relation to
prophylaxis.
It is plausible that SP may remain effective for prophylaxis
despite reduced therapeutic efficacy due to the difference in
parasite burdens between a microscopically patent blood-stage
infection (.108 parasites) and a recently inoculated parasite on
emergence from the exo-erythrocytic schizont (approximately 105
parasites) [31]. If this is the case, recrudescence due to drug
resistance may commonly detract from the prophylactic protection
Table 2. Protective efficacy of IPT against clinical malaria,
high parasite density malaria and anaemia.
Protective Efficacy (95% confidence interval)
Endpoint Clinical malaria
High parasite
density malaria Anaemia
Week since most recent IPTi
1 66.6 (48, 78) 75.1 (53, 87)
2 88.0 (75, 94) 86.3 (61, 95) 94.5 (58, 99)
3 81.3 (69, 89) 84.9 (69, 93)
4 70.2 (54, 81) 73.5 (53, 85) 92.9 (46, 99)
5 64.5 (45, 77) 70.9 (45, 85)
6 37.9 (10, 57) 39.7 (4, 62) 20.3 (2198, 79)
7 25.9 (24, 47) 8.5 (237, 39)
8 5.1 (235, 34) 20.4 (255, 35) 48.0 (29, 75)
9 231.4 (290, 9) 218.3 (284, 24)
10 13.6 (223, 39) 25.4 (262, 32) 1.0 (2183, 65)
11 8.2 (230, 35) 21.5 (218, 48)
12 11.7 (223, 37) 26.7 (260, 29) 226.6 (181, 43)
16 27.6 (234, 14) 219.1 (254, 8) 13.2 (284, 59)
20 28.1 (237, 15) 29.7 (247, 18) 262.7 (2247, 24)
Protective efficacy of IPTi by week since treatment for all IPT doses combined.
Protective efficacy is shown against clinical malaria (history of fever or
temperature $37.5uC plus malaria parasites detected on a blood smear), high
parasite density malaria (clinical malaria with parasite density $5000 parasites/
ml) and anaemia (packed cell volume ,24%). All episodes that occurred before
two years of age were included in the analyses. No long term protection was
observed; for brevity estimates are presented up to twenty weeks following
treatment. Fewer episodes of anaemia made it necessary to stratify follow-up
every two weeks for this endpoint.
doi:10.1371/journal.pone.0002227.t002
Duration of IPT Protection
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given by SP when used for IPT and partnering with another
effective antimalarial could help eliminate existing high density
infections and maximise the protection given. Amodiaquine is one
candidate for this role, having been successfully partnered with SP
for IPT in children in Senegal [12].
Conclusion
In all analyses there was strong evidence of a beneficial effect of
IPT up to four weeks after treatment and in some cases this
appeared to last up to five or six weeks. The largest drop in
protective efficacy against both clinical malaria and high parasite
density malaria was between five and six weeks after IPT (table 2);
before this time there is a relatively gradual decline in protection.
This suggests that for children at periodic high risk of malaria in a
seasonal transmission setting, IPT given on a monthly (or
approximately monthly) basis would be better than the current
option of a prolonged interval between IPT doses. The
consequences of a single missed dose would also be less if IPT is
repeated soon afterward. As discussed, monthly IPT has already
been demonstrated as highly efficacious in Senegal and Mali
[5,9,12], but further work is needed to address the cost and
logistics of large-scale seasonal IPT.
If regular delivery of IPT during the transmission season is to
become a widespread approach to controlling malaria in areas
where the majority of the burden is concentrated in a few months,
several issues will need to be addressed. Some of these are not new:
regular intermittent treatment is akin to seasonal chemoprophy-
laxis [32]. Studies of seasonal IPT with longer follow-up are
needed to rule out existing concerns related to this strategy,
including acceleration of development of drug resistance and
impairment of development of immunity before deployment on a
wider scale.
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